Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice

Qi Chen, Michael Graham Espey, Andrew Y. Sun, Chaya Pooput, Kenneth L. Kirk, Murali C. Krishna, Deena Beneda Khosh, Jeanne Drisko, and Mark Levine
PNAS August 12, 2008 105 (32) 11105-11109; https://doi.org/10.1073/pnas.0804226105

  1. Edited by Bruce N. Ames, Children's Hospital Oakland Research Institute, Oakland, CA, and approved June 6, 2008

  2. ↵†Q.C. and M.G.E. contributed equally to this work. (received for review May 1, 2008)

Abstract

Ascorbic acid is an essential nutrient commonly regarded as an antioxidant. In this study, we showed that ascorbate at pharmacologic concentrations was a prooxidant, generating hydrogen-peroxide-dependent cytotoxicity toward a variety of cancer cells in vitro without adversely affecting normal cells. To test this action in vivo, normal oral tight control was bypassed by parenteral ascorbate administration. Real-time microdialysis sampling in mice bearing glioblastoma xenografts showed that a single pharmacologic dose of ascorbate produced sustained ascorbate radical and hydrogen peroxide formation selectively within interstitial fluids of tumors but not in blood. Moreover, a regimen of daily pharmacologic ascorbate treatment significantly decreased growth rates of ovarian (P < 0.005), pancreatic (P < 0.05), and glioblastoma (P < 0.001) tumors established in mice. Similar pharmacologic concentrations were readily achieved in humans given ascorbate intravenously. These data suggest that ascorbate as a prodrug may have benefits in cancers with poor prognosis and limited therapeutic options.

Footnotes

  • ↵‡To whom correspondence may be addressed at: Molecular and Clinical Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, 10/4D52, 9000 Rockville Pike, National Institutes of Health, Bethesda, MD 20892. E-mail: sp{at}nih.gov or mark.levine{at}nih.gov

  • Author contributions: Q.C., M.G.E., and M.L. designed research; Q.C., M.G.E., A.Y.S., D.B.K., and J.D. performed research; C.P., K.L.K., and M.C.K. contributed new reagents/analytical tools; Q.C., M.G.E., C.P., K.L.K., M.C.K., J.D., and M.L. analyzed data; and M.G.E. and M.L. wrote the paper.

  • The authors declare no conflict of interest.

  • This article is a PNAS Direct Submission.

  • See Commentary on page 11037.

  • Received May 1, 2008.
View Full Text
Back to top
Article Alerts
Email Article
Citation Tools
Request Permissions
Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice
Qi Chen, Michael Graham Espey, Andrew Y. Sun, Chaya Pooput, Kenneth L. Kirk, Murali C. Krishna, Deena Beneda Khosh, Jeanne Drisko, Mark Levine
Proceedings of the National Academy of Sciences Aug 2008, 105 (32) 11105-11109; DOI: 10.1073/pnas.0804226105
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Proceedings of the National Academy of Sciences: 116 (11)
Current Issue

Submit

Jump to section

You May Also be Interested in

PNAS Profile of NAS member and geologist Paul E. Olsen
Featured Profile
PNAS Profile of NAS member and geologist Paul E. Olsen.
Image courtesy of Kevin Krajick (Columbia University, New York).
Fossil illuminates hagfish evolution
Fossil illuminates hagfish evolution
Fossil evidence helps address a longstanding debate on the evolution of hagfish, a jawless, marine-dwelling slime “eel,” and suggests that living jawless vertebrates may not be as primitive as their anatomy suggests.
Image courtesy of Tetsuto Miyashita.

More Articles of This Classification

Related Content

Cited by...

Similar Articles